Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2019 Archives
- Net Sales, Excluding Levothyroxine, Continues Sequential Quarterly Growth Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019. "Our solid third quarter financial results reflect continued growth of... More |
Apr 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54... More |
Apr 29, 2019 Lannett To Report Fiscal 2019 Third-Quarter Financial Results, Host Conference Call On Monday, May 6 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 third quarter on Monday, May 6, 2019, after the market closes. Lannett management will... More |
Mar 27, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aspirin and... More |
Mar 21, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions. The purchases... More |
Mar 11, 2019 --Company Expects to Commence Marketing the Product Near Term-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of... More |
Feb 26, 2019 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 40th Annual Institutional Investors Conference at 1:05 p.m.... More |
Feb 6, 2019 - Recent 17 Product Launches Contributed $40 Million of Net Sales in Fiscal 2019 YTD Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 second quarter ended December 31, 2018. "Stellar sales across our product offering drove our strong fiscal... More |
Feb 6, 2019 Product Launches, Cost Savings, Insulin Glargine
|
Jan 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes. Lannett... More |
Jan 22, 2019 Company Has Begun Marketing Entacapone IR Tablets Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules,... More |
| 1-25 26-36 |